Aline B Maddux1, Peter M Mourani2, Russell Banks3, Ron W Reeder3, Murray M Pollack4, Robert A Berg5, Kathleen L Meert6, Patrick S McQuillen7, Andrew R Yates8, Daniel A Notterman9, John T Berger4. 1. Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado. aline.maddux@childrenscolorado.org. 2. Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas. 3. University of Utah, Salt Lake City, Utah. 4. Children's National Health System, Washington, DC. 5. The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 6. Children's Hospital of Michigan, Detroit, Michigan. 7. Benioff Children's Hospital, San Francisco, California. 8. Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio. 9. Department of Molecular Biology, Princeton University, Princeton, New Jersey.
Abstract
BACKGROUND: Inhaled nitric oxide (INO) is used to treat hypoxic respiratory failure without clear evidence of benefit. Future trials to evaluate its use will be designed based on an understanding of the populations in which this therapy is provided and with outcomes based on patient characteristics, for example, a history of premature birth. METHODS: This was a multi-center prospective observational study that evaluated subjects in the pediatric ICU who were treated with INO for a respiratory indication, excluding those treated in the neonatal ICU or treated for birth-related disease. We used logistic regression to evaluate characteristics associated with mortality and duration of mechanical ventilation. Specifically, we compared subjects born early preterm (<32 weeks post-conceptual age), late preterm (32-37 weeks post-conceptual age), and full term. RESULTS: A total of 163 children (median age [interquartile range], 1.8 [0.7-6.0] y) were included, 41 (25.2%) had a history of preterm birth (18 born early preterm and 23 born late preterm). INO was initiated for less-severe lung disease in the early preterm versus late preterm versus full-term subjects (median mean airway pressures, 16 vs 19 vs 19 cm H2O; P = .03), although the oxygenation index and oxygenation saturation index did not differ. The early preterm subjects had more ventilator-free days (median, 18.0, 7.0, 4.5 d; P = .02) and lower 28-d mortality (0, 26.1, 32.0%; P = .007). Lower respiratory tract disease, but not a history of prematurity, was independently associated with lower mortality. CONCLUSIONS: INO was used differently in early preterm subjects. Clinical trials that evaluate INO use should have standardized oxygenation deficit thresholds for initiation of therapy and should consider stratifying by early preterm status.
BACKGROUND: Inhaled nitric oxide (INO) is used to treat hypoxic respiratory failure without clear evidence of benefit. Future trials to evaluate its use will be designed based on an understanding of the populations in which this therapy is provided and with outcomes based on patient characteristics, for example, a history of premature birth. METHODS: This was a multi-center prospective observational study that evaluated subjects in the pediatric ICU who were treated with INO for a respiratory indication, excluding those treated in the neonatal ICU or treated for birth-related disease. We used logistic regression to evaluate characteristics associated with mortality and duration of mechanical ventilation. Specifically, we compared subjects born early preterm (<32 weeks post-conceptual age), late preterm (32-37 weeks post-conceptual age), and full term. RESULTS: A total of 163 children (median age [interquartile range], 1.8 [0.7-6.0] y) were included, 41 (25.2%) had a history of preterm birth (18 born early preterm and 23 born late preterm). INO was initiated for less-severe lung disease in the early preterm versus late preterm versus full-term subjects (median mean airway pressures, 16 vs 19 vs 19 cm H2O; P = .03), although the oxygenation index and oxygenation saturation index did not differ. The early preterm subjects had more ventilator-free days (median, 18.0, 7.0, 4.5 d; P = .02) and lower 28-d mortality (0, 26.1, 32.0%; P = .007). Lower respiratory tract disease, but not a history of prematurity, was independently associated with lower mortality. CONCLUSIONS: INO was used differently in early preterm subjects. Clinical trials that evaluate INO use should have standardized oxygenation deficit thresholds for initiation of therapy and should consider stratifying by early preterm status.
Authors: Punkaj Gupta; Troy Richardson; Matthew Hall; David Bertoch; Kiran B Hebbar; James D Fortenberry; Randall C Wetzel Journal: Crit Care Med Date: 2016-10 Impact factor: 7.598
Authors: Michael W Quasney; Yolanda M López-Fernández; Miriam Santschi; R Scott Watson Journal: Pediatr Crit Care Med Date: 2015-06 Impact factor: 3.624
Authors: Peter M Mourani; John P Kinsella; Gilles Clermont; Lan Kong; Amy M Perkins; Lisa Weissfeld; Gary Cutter; Walter T Linde-Zwirble; Steven H Abman; Derek C Angus; R Scott Watson Journal: J Pediatr Date: 2013-12-31 Impact factor: 4.406
Authors: Ronald A Bronicki; James Fortenberry; Michael Schreiber; Paul A Checchia; Nick G Anas Journal: J Pediatr Date: 2014-11-12 Impact factor: 4.406
Authors: Peter M Mourani; Erica W Mandell; Maxene Meier; Adel Younoszai; John T Brinton; Brandie D Wagner; Sanne Arjaans; Brenda B Poindexter; Steven H Abman Journal: Am J Respir Crit Care Med Date: 2019-04-15 Impact factor: 21.405
Authors: Murray M Pollack; Richard Holubkov; Penny Glass; J Michael Dean; Kathleen L Meert; Jerry Zimmerman; Kanwaljeet J S Anand; Joseph Carcillo; Christopher J L Newth; Rick Harrison; Douglas F Willson; Carol Nicholson Journal: Pediatrics Date: 2009-07 Impact factor: 7.124
Authors: Murray M Pollack; Richard Holubkov; Tomohiko Funai; John T Berger; Amy E Clark; Kathleen Meert; Robert A Berg; Joseph Carcillo; David L Wessel; Frank Moler; Heidi Dalton; Christopher J L Newth; Thomas Shanley; Rick E Harrison; Allan Doctor; Tammara L Jenkins; Robert Tamburro; J Michael Dean Journal: Crit Care Med Date: 2015-08 Impact factor: 7.598